Get the Stockscreener App
0.1104
23.23%
-0.0334
Aptose Biosciences Inc Stock (APTO) Latest News
Aptose Biosciences (NASDAQ:APTO) Now Covered by StockNews.com - Defense World
Aptose Biosciences Stock to Reverse Split on Wednesday, February 26th (NASDAQ:APTO) - Defense World
Aptose Biosciences finalizes reverse stock split By Investing.com - Investing.com Canada
Aptose Biosciences finalizes reverse stock split - Investing.com
Aptose's leukemia drug cleared to double clinical trial dose - MSN
Aptose Announces Positive Clinical Safety Review Committee - GlobeNewswire
Aptose advances AML treatment with higher dose in trial By Investing.com - Investing.com Nigeria
Why Is Penny Stock Aptose Biosciences Trading Higher On Thursday? - Benzinga India
Aptose Biosciences Moves Forward With TUS Escalation In TUSCANY Trial After Positive Data - Nasdaq
Aptose's leukemia drug cleared to double clinical trial dose | 2025-02-20 | Investing News - Stockhouse Publishing
Aptose advances AML treatment with higher dose in trial - Investing.com India
Aptose Biosciences Brief: This Amid "Complete Responses and Favorable Safety in First Cohort" - Marketscreener.com
Aptose Biosciences Brief: Announcing "Positive" Clinical Safety Review Committee Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib - Marketscreener.com
Breakthrough in AML Treatment? Aptose's Triple Drug Therapy Achieves Complete Responses in First Trial Cohort - StockTitan
Aptose Biosciences, Inc. to Host Earnings Call - ACCESS Newswire
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga India
US Stocks Likely To Open Lower Following Fresh Records From Previous Session: Expert Says, 'Don't Be Scared Of New Highs' - Benzinga
Aptose Biosciences plans reverse stock split to meet Nasdaq rules By Investing.com - Investing.com Canada
Aptose Biosciences approves 1-for-30 reverse share split to restore Nasdaq compliance - MSN
Aptose Biosciences Announces Reverse Share Split - TipRanks
Aptose Biosciences plans reverse stock split to meet Nasdaq rules - Investing.com India
Aptose Biosciences Inc. Announces Reverse Share Split to Enhance Compliance with Nasdaq Listing Requirements - Nasdaq
Aptose Announces Reverse Share Split - GlobeNewswire
Aptose Takes Bold Action: 30-to-1 Share Consolidation to Secure Nasdaq Future - StockTitan
US Stocks Likely To Open Higher Amid Ukraine Peace Talk Hopes As Russian, American Officials Meet - Benzinga
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket - Benzinga
Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com - Defense World
Aptose Biosciences announces resale of 12.03M shares by Keystone Capital Partners - MSN
Aptose Biosciences secures $25 million equity facility - MSN
Aptose Biosciences (NASDAQ:APTO) Earns “Buy” Rating from HC Wainwright - Defense World
Aptose Biosciences Inc. (NASDAQ: APTO) Issues Press Release on February 12, 2025 - Defense World
Aptose Biosciences Secures $25M Share Purchase Agreement - TipRanks
Aptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market Facility - GlobeNewswire
Aptose Biosciences secures $25 million equity facility By Investing.com - Investing.com Canada
Aptose Biosciences Enters $25 Million Common Share Purchase Agreement to Support AML Therapy Development - Nasdaq
Major Funding Alert: Aptose Locks $26M Total Financial Flexibility in Strategic Move - StockTitan
Aptose Biosciences Establishes $25M Equity Facility - TipRanks
Aptose’s Frontline Triple Drug Therapy with Tuspetinib - GlobeNewswire
Aptose Biosciences' leukemia drug shows early promise - MSN
Chefs' Warehouse, Aptose Biosciences, Electromed - TradingView
Aptose Biosciences' leukemia drug shows early promise | 2025-02-12 | Investing News - Stockhouse Publishing
Aptose Biosciences rises on safety results from early-stage cancer therapy trial - TradingView
PyroGenesis Inc. - Baystreet.ca
TerraVest Industries Inc. - Baystreet.ca
Aptose Biosciences Inc. - Baystreet.ca
Troy Minerals Inc. - Baystreet.ca
Payfare Inc. - Baystreet.ca
Buhler Industries Inc. - Baystreet.ca
Promising Results from Aptose Biosciences’ TUSCANY Trial Boost Joseph Pantginis’ Buy Rating - TipRanks
APTOAptose Reports Results for the Second Quarter 2024 - ADVFN
Aptose Up 20% In US Premarket After Update On Its Frontline Triple Drug Therapy With Tuspetinib - Marketscreener.com
Promising Early Results from Aptose’s TUSCANY Trial in AML Treatment - TipRanks
Aptose Biosciences Brief: Says Its Frontline Triple Drug Therapy With Tuspetinib Achieved "Notable Responses" In Newly Diagnosed AML Patients In Phase 1/2 TUSCANY Trial - Marketscreener.com
0.53%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):